Reagent: HeLa-tat-III Cells

Catalog Number: 502

Lot Number: 100202A

Release Category: D

Provided: 5 x 10^6 cells/mL. Viability is 96%.

Propagation Medium: DMEM, 93%; horse serum, 7%.

Freeze Medium: DMEM, 50%; fetal bovine serum, 40%, DMSO, 10%.

Growth Characteristics: These adherent cells grow to a confluent culture in 3-4 days. Split 1:10. Horse serum is optional for cultivating the cells. They can be maintained as adherent cultures in 10% fetal bovine serum. Horse serum is necessary to maintain the cells as suspension cultures; however, once the cells are grown in FBS they cannot be easily grown in horse serum again.

Sterility: Negative for mycoplasma, bacteria and fungi.

Description: HeLa parental cells stability transfected to express HXBc2 tat.

Special Characteristics: Human cervical epithelial carcinoma. Normal epithelial appearance. The parental HeLa cell line was transfected with a Moloney-based retroviral vector containing a SalI-BamHI segment from the HIV-1 genomic clone pHXBc2 and a neomycin selection marker. Clones were selected for neomycin-resistance and screened for their ability to trans-activate a transfected HIV-1 LTR. Because expression of the tat protein is stable, the cells can be grown for weeks in the absence of neomycin. If expression drops, the cells can be grown in the presence of 800 µg/mL neomycin.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
Recommended Storage: Liquid nitrogen

Contributor: Dr. William Haseltine, Dr. Ernest Terwilliger and Dr. Joseph Sodroski.


NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HeLa-tat-III Cells from Drs. William Haseltine, Ernest Terwilliger and Joseph Sodroski." Also include the references cited above in any publications.

This and other stable cell lines expressing tatIII is described in US Patent #4,981,790. Requests from commercial organizations should be directed to Dr. Joseph Sodroski, Division of Human Retrovirology, JB24, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA, 02115.

Commercial requestors of HeLa-tat-III must also contact the Director, Office of Technology Transfer, Dana-Farber Cancer Institute, 44 Binney Street, Suite L660, Boston, MA 02115.

Last Updated July 02, 2018